Scientists probe DNA marks to explain cystic fibrosis lung decline
NCT ID NCT02884622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 72 adults with cystic fibrosis to see if chemical changes in DNA, called methylation, are linked to how well their lungs work. The goal was to understand why lung disease gets worse at different rates in different people. No treatment was given; instead, researchers measured DNA methylation levels and compared them to lung function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
72 people
The number who actually took part.
- Start date
-
Jun 2013
- Finished
-
Aug 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \>18 years old * homozygous for the F508del mutation Exclusion Criteria: * subjects who have an active CF exacerbation or a recent viral infection on the day of biological samples collection; * pregnant women; * patients who are included in interventional medical trials; * patients who had lung transplantation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UHMontpellier
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?